L3Harris Technologies Inc vs uniQure N.V. Ordinary Shares — how do they compare? L3Harris Technologies Inc trades at $237.93 (market cap $43.71B), while uniQure N.V. Ordinary Shares trades at $20.78 (market cap $1.48B). The key difference: L3Harris Technologies Inc is far larger — about 29.5× uniQure N.V. Ordinary Shares's market cap, and L3Harris Technologies Inc pays a 2.13% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold L3Harris Technologies Inc for 56 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| LHX | QURE | |
|---|---|---|
Market Cap | $43.71B | $1.48B |
Volume | 1,558,148 | 2,488,780 |
Sector | Industrials | Health |
52-Week High | $378.48 | $70.59 |
52-Week Low | $233.63 | $9.03 |
Typical Hold Time | 56 Days | 0 Days |
Enterprise Value | $54.15B | $728.62M |
Dividend Yield | 2.13% | — |
Signals from Pluang's Aura AI — not financial advice
LHX trades at $237.50, down 0.31% with a bearish technical signal. The company shows solid fundamentals with consistent earnings beats, revenue growth from $21.3B to $21.9B (2024-2025), and a net income margin improving to 7.34%. Recent news includes a $6B THAAD propulsion contract but also multiple law firm investigations into investor claims, creating mixed sentiment.
Outlook: Strong defense budget tailwinds and recent contract wins support growth, but legal scrutiny and bearish technicals pose near-term risks. Analyst consensus is bullish with a $340 price target (43% upside), highlighting value if legal concerns resolve favorably.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →